🧬 With biomedical PhD applications open now, I often get asked for advice. I created a guide filled with tips from my own journey to Harvard & insights from others. I use it to lead workshops & it’s ready to help you too! ✨
Dive in and share! ⬇️
yaelcourtney.com/phdapplicat…
Personal news: in September I traveled to marry this incredibly handsome, kind, patient Australian man 🇦🇺💍. We had a perfect day supported by SO many family and friends from near and far.
Kyle, thank you for supporting me in everything I do. You make it all possible. 🧵 1/3
Shameless plug: I'm hoping to start a lab in Melbourne studying how herpesviruses contribute to autoimmunity, brain disease, and post-infectious syndromes. If you know of openings or want to talk science, my DMs are open. 3/3
We met in Boston and always planned to end up in Australia. Kyle moved to California with me for ~3 years so I could do my dream postdoc at Stanford, far from his family and friends. I hope we're back in Aus by 2028, ideally with me as faculty 🤞 2/3
Stanford researchers studied 27 autoimmune patients and found CD19 CAR T-cell therapy cleared EBV-infected, autoreactive B cells that resisted rituximab.
8 of 12 CAR T-cell patients achieved sustained drug-free remission.
biorxiv.org/content/10.64898…
8 of 12 people with autoimmune disease got a single infusion of CAR-T cells and went into lasting remission - years, no drugs.
With rituximab, the standard way of wiping out B cells, 0 of 15 did. A new preprint argues the gap comes down to one kind of cell - a B cell infected with EBV.🧵
Stanford researchers studied 27 autoimmune patients and found CD19 CAR T-cell therapy cleared EBV-infected, autoreactive B cells that resisted rituximab.
8 of 12 CAR T-cell patients achieved sustained drug-free remission.
biorxiv.org/content/10.64898…
15/ This manuscript was a HUGE effort across Stanford @StanfordRheum, Erlangen (CASTLE) & Leiden (SYNBIOSE-II), supervised by Bill Robinson, Georg Schett & @grieshaber, with Laura van Dam, @younis_sh1, Sajede Rasouli, Mengrui Zhang, Yashaar Chaichian, @TobiasLanz and many more!
14/ If the EBV+ autoreactive B cell decides durability, you may not need manufactured CAR T cells to clear it. A T-cell engager matched CAR T killing in vitro.
It also makes repertoire reset worth testing prospectively.
13/ 8 of 12 CAR T patients stayed in drug-free remission at a median 31 months, against 0 of 15 on rituximab. Four relapsed: one with persisting EBV+ clonotypes, one with a newly infected autoreactive clone.
Both routes the model predicts.
12/ A possible reason antibodies fail: Latency III drives NF-κB survival signaling, and EBV+ cells upregulated CD55, tied to rituximab resistance in B cell cancers.
Four anti-CD20/CD19 antibodies killed EBV+ targets poorly in vitro. CAR T cells and blinatumomab did fine.
11/ The cells surviving rituximab weren’t dormant. Against depth-matched EBV− cells they scored higher on MHC I, MHC II, antigen processing and activation in all 7 patients, with antigen presentation the top GSEA hit (NES 2.05, q=0.010).
10/ And the latency distribution was similar before versus after CAR T, in cells that were newly infected.
Therapy left the virus and its program in place while changing which clones carry them. What tracked with remission was the specificity of those cells.
9/ EBV+ cells in healthy donors were entirely Latency 0/I. A large fraction of patient EBV+ cells ran Latency III, the program expressing EBNA2 and LMP1, which in healthy carriers appears only in freshly infected cells.
8/ We cloned 50 antibodies from individual EBV+ B cells and tested them on human cells.
Before therapy: 12 of 14 autoreactive.
After CAR T, in remission: 1 of 10.
After rituximab: 15 of 19.
EBV− repertoire, same patients: 6 of 40.